Posted by Michael Wonder on 28 Mar 2025
Crinetics Pharmaceuticals announces EMA validation of marketing authorisation application and orphan drug designation for paltusotine in acromegaly
27 March 2025 - Crinetics Pharmaceuticals today announced that the EMA has validated the marketing authorisation application for paltusotine, the first once daily, oral, selectively-targeted somatostatin receptor type 2 non-peptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterised by consistently elevated levels of growth hormone.
Additionally, the EMA on 27 February 2025 granted paltusotine orphan drug designation for the treatment of acromegaly.
